Work

Ultrafast breast DCE-MRI: comparative analysis of semi-quantitative and pharmacokinetic parameters with gadoterate meglumine versus gadobutrol in malignant lesions and background parenchymal enhancement

Year: 2025

Type: article

Abstract: Background: ) in ultrafast breast dynamic contrast-enhanced MRI (DCE-MRI), focusing on semi-quantitative and pharmacokinetic parameters for differentiating malignant lesions from background parenchymal enhancement (BPE). Methods: (volume transfer constant) and Ve [extravascular extracellular space (EES) fractional volume], are calculated with the Tofts model. The individual arterial input function (AIF) was traced over an ROI within the descending thoracic aorta that was utilized to calibrate the time course of average signal intensity. Diagnostic performance was measured by sensitivity, specificity, and area under the receiver operating characteristic curve (AUROC) at Youden-optimized thresholds. Inter-agent comparisons included Wilcoxon rank-sum testing and Cohen's d effect sizes. Results: 0.58; P=0.036); however, the clinical significance of this difference remains uncertain. Conclusions: In ultrafast breast DCE-MRI, Gadavist demonstrated stronger early enhancement kinetics, whereas Dotarem provided improved tumor-to-BPE contrast and higher sensitivity for select kinetic parameters. These findings underscore the importance of tailoring contrast agent selection to specific diagnostic goals.

Source: Quantitative Imaging in Medicine and Surgery

DOI: 10.21037/qims-2025-1111

Authors: Saengsiri Chumsaengsri, Hiroyuki Abe, Gregory S. Karczmar, Zhen Ren, Kirti Kulkarni

Institutions: University of Chicago, Chulabhorn Hospital, Chulabhorn Royal Academy

Language: English

Topic: MRI in cancer diagnosis

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: National Institutes of Health